Trial Outcomes & Findings for VircapSeq Virus Detection in Sézary Syndrome (NCT NCT02836886)

NCT ID: NCT02836886

Last Updated: 2024-05-28

Results Overview

Recruitment status

COMPLETED

Target enrollment

6 participants

Primary outcome timeframe

Through study completion, an average of 4 months

Results posted on

2024-05-28

Participant Flow

Participant milestones

Participant milestones
Measure
Sézary Syndrome
Patients diagnosed with Sézary syndrome diagnosed according to the WHO-EORTC criteria.
Overall Study
STARTED
6
Overall Study
COMPLETED
6
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

VircapSeq Virus Detection in Sézary Syndrome

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Sézary Syndrome
n=6 Participants
Patients diagnosed with Sézary syndrome diagnosed according to the WHO-EORTC criteria.
Age, Categorical
<=18 years
0 Participants
n=93 Participants
Age, Categorical
Between 18 and 65 years
5 Participants
n=93 Participants
Age, Categorical
>=65 years
1 Participants
n=93 Participants
Age, Continuous
65 years
n=93 Participants
Sex: Female, Male
Female
5 Participants
n=93 Participants
Sex: Female, Male
Male
1 Participants
n=93 Participants
Region of Enrollment
United States
6 participants
n=93 Participants

PRIMARY outcome

Timeframe: Through study completion, an average of 4 months

Outcome measures

Outcome measures
Measure
Sézary Syndrome
n=6 Participants
Patients diagnosed with Sézary syndrome diagnosed according to the WHO-EORTC criteria.
Number of Participants With Viral Sequences Present in Malignant T Cells of Patients With Sézary Syndrome
6 Participants

OTHER_PRE_SPECIFIED outcome

Timeframe: Through study completion, an average of 4 months

Outcome measures

Outcome measures
Measure
Sézary Syndrome
n=6 Participants
Patients diagnosed with Sézary syndrome diagnosed according to the WHO-EORTC criteria.
Number of Coding Sequences for Viral Pathogens Extracted From T Cells of Patients With Sézary Syndrome
0 coding sequences for viral pathogens

Adverse Events

Sézary Syndrome

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Larisa Geskin, MD

Columbia University

Phone: 2123055550

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place